Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zydus files IND application for dyslipidemia compound

This article was originally published in Scrip

Executive Summary

Zydus Cadilahas filed an IND for a lipid lowering molecule with the Drugs Controller General of India. The company claims that the new compound, ZYT1, may provide an alternative to statins or be an add-on to statin therapy. In preclinical studies, ZYT1 has shown a beneficial effect on LDL-cholesterol and triglycerides, compared with the effects seen with statins. When combined with statins, ZYT1 has shown a "pronounced effect" in lowering LDL-cholesterol and triglycerides and has a very high margin of safety, Zydus said. The company now has six compounds in various stages of clinical development, with two candidates in advanced Phase II. The company's R&D is focused on the metabolic, cardiovascular and inflammation segments.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC030361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel